|
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Pertuzumab is a humanized monoclonal antibody that inhibits human epidermal growth factor receptor 2 (HER2) heterodimerization and has single-agent activity in recurrent epithelial ovarian cancer.
|
19901115 |
2010 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Patients with advanced breast or ovarian cancer that overexpressed HER-2/neu were eligible for treatment.
|
7545221 |
1995 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we show that small interfering RNA (siRNA) can silence the expression of Her-2/neu in models of human breast or ovarian cancer through retrovirus-mediated transfer of an siRNA against Her-2/neu.
|
14625284 |
2004 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The HER2 oncogene and its relative oncoprotein, gp185HER2, a transmembrane glycoprotein belonging to the epidermal growth factor receptor family, are overexpressed in a wide range of solid tumors including breast and ovarian cancer.
|
11394499 |
2001 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The receptors for HER2 are overexpressed in various human cancers, such as breast and ovarian cancer.
|
31470531 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
CTD_human |
In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer.
|
28811376 |
2017 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
HER-2/neu is a proto-oncogene associated with poor prognosis in women with breast and ovarian carcinoma.
|
10202671 |
1999 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Therefore, neither c-erbB2 gene amplification nor c-erbB2 protein over-expression appears to be a significant prognostic marker in patients with ovarian carcinoma.
|
7615357 |
1995 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Amplifications and overexpression of various EGFR family members, including EGFR, Her2, and ErbB3, have been reported in epithelial ovarian cancer.
|
21364581 |
2011 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
HER-2/neu expression does not appear to be an important prognostic factor in patients with advanced epithelial ovarian cancer.
|
8093588 |
1993 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model.
|
16166319 |
2005 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tests for the HER2 gene copies per tumor cell either before or after correction of chromosome-17 can be applied as a potentially valuable tool to analyze the HER2 status in mucinous EOC.
|
24656091 |
2014 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
No genomic rearrangements by Southern blotting were seen in the brcAI candidate gene estradiol 17 beta dehydrogenase 2 (17hsd2), or in erbB2, prohibition (phb) and nmeI (previously nm23-HI).
|
8098014 |
1993 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Activation of c-erbB-2 and prognosis in ovarian carcinoma. Comparison with histologic type, grade, and stage.
|
7906608 |
1994 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of the multicenter study is to investigate the correlation between the expression of estrogen alpha receptors (ERα), progesterone receptors (PR), human epidermal growth factor receptor 2 (HER2), stromal cell-derived factor 1 (SDF1) and its receptor C-X-C chemokine receptor type 4 (CXCR4), breast cancer metastasis suppressor 1 (BRMS1), astrocyte elevated gene 1 (AEG1), depending on the status of BRCA1 protein, in patients suffering from OC and BC with brain metastases.
|
30822630 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
c-erbB-2 oncogene expression in ovarian cancer.
|
2266460 |
1990 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of the HER2/neu oncogene (also known as c-erbB2) is a frequent molecular event in multiple human cancers, including breast and ovarian cancer.
|
11774202 |
2001 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
The CTLs were capable of lysing low doses of peptides pulsed into target cells or OC Her-2/neu(+) tumors.
|
19115932 |
2008 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aptamer-radionuclide conjugate was evaluated for cellular HER2-specific binding, saturation affinity, and cellular internalization in SKOV-3 and MCF-7 cells, and its biodistribution properties were assessed in normal and SKOV-3 tumor-bearing mice.
|
23953624 |
2013 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of HER2/HER3 and clinical feature of ovarian cancer.
|
31328457 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
We demonstrated that both chromosome-17 corrected and uncorrected HER2 gene copies correlated significantly with HER2 IHC result categories; and tests for the HER2 gene copies per tumor cell either before or after correction for chromosome-17 can be applied as a potentially valuable tool in analyzing the HER2 status in EOC.
|
21046136 |
2011 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Forty-five patients with stage III or IV HER-2/neu overexpressing breast or ovarian cancer were evaluated for HER-2/neu specific T cell and antibody immunity.
|
11072789 |
2000 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results demonstrated that Gigantoxin-4-4D5 scFv exerted a highly cytotoxic effect on the HER2/neu-positive ovarian carcinoma SK-OV-3 cell line.
|
27063011 |
2016 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to investigate the potential prognostic value of SKP2, genes P27Kip1, K-ras, c-Myc, COX2 and HER2 genes expression in ovarian cancer.
|
26320455 |
2015 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, HER2 gene status was evaluated in a large, multicentric series of 320 patients with advanced ovarian cancer, including 243 patients enrolled in a multicenter prospective clinical trial of paclitaxel/carboplatin-based chemotherapy.
|
17987122 |
2007 |